International Gynecologic Cancer Society (IGCS) — Annual Global Meeting (IGCS 2026)

The IGCS 2026 Annual Global Meeting is scheduled for October 1–3, 2026 in Montréal, Canada. This meeting is organized by the International Gynecologic Cancer Society (IGCS) and is positioned as a multidisciplinary gathering focused on advancing prevention, treatment, research, and quality of life for women affected by gynecologic cancers.

1) Who attends (BUYERS / ATTENDEES)

IGCS 2026 is not only a medical-science conference—it is a clinical, research, and multidisciplinary oncology community meeting. That means “buyers” in practice often come from roles that influence: clinical programs, trial networks, continuing medical education planning, oncology practice pathways, advocacy initiatives, research funding ecosystems, and provider decision-making for technologies and services.

Main attendee groups we expect

• Oncology clinicians and specialists (gynecologic oncology, medical oncology, radiation oncology, pathology and allied specialties)
• Researchers and investigators working on prevention, translational research, clinical trials, and survivorship
• Multidisciplinary care teams (tumor boards, integrated care pathways, survivorship programs)
• Healthcare educators and medical education professionals responsible for CME/CPD planning and scientific content
• Radiation and treatment-planning stakeholders due to dedicated educational workshops (e.g., radiation contouring workshop)
• Advocacy and patient-impact leadership given the presence of an advocacy summit
• Industry partners supporting scientific programming, sponsorship, exhibits, and sponsored learning activities
• Early career researchers and academic trainees (supported by an Early Career Network)
• Clinical trial network and protocol leadership (often present at society meetings where collaboration is a core theme)

Best buyer-style decision-maker profiles to target

• Medical Affairs leadership (especially those covering women’s oncology/gynecologic oncology)
• Clinical Operations / Clinical Trial Management leaders for trial execution, site networks, and protocol oversight
• Medical Education / Scientific Affairs leaders for CME/CPD-linked programs and faculty development
• Radiation Oncology program leaders and treatment planning stakeholders
• Patient advocacy / access / outcomes leaders who shape awareness and education initiatives
• Commercial leaders in oncology who require conference attendance for KOL engagement and partnership building
• Research leadership who build collaborations and shape investigator-initiated or network trials

2) Where the show is happening + attendee geographic origin

Location (city/country): Montréal, Canada
Dates: October 1–3, 2026

IGCS describes itself as uniting the globe since 1985, and the meeting is presented as an international community event. Therefore, the expected attendee geographic origin is global, with a strong North American presence due to venue location in Canada, and additional representation across Europe, Asia-Pacific, and other regions where gynecologic oncology societies and academic centers are active.

Geographic targeting that typically performs best

• Canada + United States: highest density for oncologists, healthcare institutions, and regional industry teams
• Europe: strong participation from academic medical centers and clinical research networks
• Asia-Pacific: growing oncology research presence, especially where international trial collaborations exist
• Global (cross-border collaboration-focused roles): medical affairs, clinical trial leadership, and research network stakeholders

3) Audience reach (Local / National / Global)

This event’s audience reach is best categorized as Global. While it occurs in Montréal, IGCS positioning emphasizes global community building, cross-border collaboration, and an international multidisciplinary exchange.

• Local: Montréal and Québec institutions will contribute attendees and faculty
• National: Canada-based academic and clinical stakeholders will be well represented
• Global: internationally distributed clinicians, researchers, and industry partners are part of the core value proposition

4) Sample buyer company names (BUYERS ONLY) + websites

Below is a provisional buyer shortlist constructed around organizations that typically align with society-led oncology meetings: pharmaceutical/biotech in gynecologic oncology, clinical research services, oncology education and publishing ecosystems, radiation oncology technology, and trial/network enablement providers.

To refine this to the best buyers for our client’s exact needs, we need the client’s website (see Section 8).

Note: Rows 19–20 are placeholders because the client’s product category (technology, services, analytics, device, education, patient support, etc.) determines which buyer segment is truly most relevant. We can finalize these once we receive the client website.

5) Job profiles, industries & event type

Industries most aligned with IGCS 2026 (expected buyer sectors)

• Pharmaceuticals and Biotechnology (oncology therapeutics)
• Medical Devices and Radiation Oncology Technology (treatment planning and workflows)
• Clinical Research / CRO & Trial Networks (clinical development stakeholders)
• Healthcare & Hospital Systems (clinical program leadership)
• Medical Education & CME/CPD ecosystem
• Publishing & Scientific Communications
• Market Research / Healthcare Insights (evidence, outcomes, and adoption insights)
• Patient Advocacy / Nonprofit Healthcare (outcomes and lived-experience impact)

Event type

IGCS 2026 is a medical conference / multidisciplinary oncology society meeting with:

• Scientific Program
• Faculty and Early Career Network
• Workshops (including a radiation contouring workshop)
• Advocacy Summit
• CME/CPD Accreditation

Job profiles to target (high relevance)

• Medical Affairs Director / Medical Lead (Oncology / Women’s Cancers / Gynecologic Oncology)
• Clinical Trial / Clinical Operations Director
• Clinical Research Partnerships Manager
• CME/CPD Program Director / Medical Education Manager
• Radiation Oncology Clinical Applications Manager
• Treatment Planning / Contouring Workflow Lead
• Scientific Program Committee Support / Evidence & Outcomes Lead
• Advocacy Strategy Lead / Patient Impact Director
• Academic Research Director / Translational Research Lead
• Oncology Product Marketing Director (when the product supports cancer care pathways)

6) Estimated attendance (expected total footfall)

The official site content provided here does not include a specific attendance number. To avoid guessing, we will treat attendance as not reliably stated based on the provided source text.

For a high-performing buyer list strategy, we focus on role density rather than only footfall: IGCS includes CME/CPD, workshops, and an advocacy summit—these increase the likelihood of attracting the exact buyer decision-makers from medical affairs, clinical operations, medical education, radiation workflows, and advocacy leadership.

7) Key focus areas & buyer engagement

Key focus areas reflected by the program themes

• Latest research exchange across gynecologic cancer prevention, treatment, and study
• Practice updates for improved outcomes and quality of life
• Multidisciplinary collaboration to transcend borders and build partnerships
• Workshops such as radiation contouring (suggesting high interest in radiation planning competency)
• Advocacy (advocacy summit indicates involvement from patient advocacy and policy-impact stakeholders)
• Early Career Network (suggesting engagement from young investigators and academic trainees)

How buyers typically want to engage

• Scientific credibility: buyers respond well to research-aligned positioning and faculty-adjacent conversations
• Clinical implementation relevance: workshops and practice update themes mean buyers look for workflow and adoption stories
• Global partnership potential: cross-border collaboration is a core stated value—buyers often seek international trial or practice links
• CME/CPD fit: if a buyer is in education, they will engage with content, accreditation, and faculty support models

Buyer engagement angles we recommend we use (without assuming the product)

• “We help you connect with gynecologic oncology medical affairs and evidence-generation decision-makers active at IGCS 2026.”
• “We help you reach clinical research and trial operations leadership engaged in global collaboration networks.”
• “We help you locate radiation oncology workshop-relevant stakeholders for contouring/treatment planning and workflow improvements.”
• “We help you identify advocacy and patient-impact stakeholders for education and awareness partnerships.”

8) Client-product fit check (we need your website)

To recommend the best buyer targets for this conference based on our client’s exact requirements, we must review the client product category using their website. Please share the client website (URL) and answer these two quick questions:

• What do we sell? (device / software / services / education / patient support / CRO / analytics / staffing / publishing, etc.)
• Who is the buyer persona? (medical affairs, clinical operations, education/CME, radiation workflow, research leadership, advocacy, procurement, etc.)

How we will tailor the IGCS 2026 buyer list once we get the website

• If the client offers therapies or oncology services: we prioritize medical affairs + clinical research partnerships + evidence generation roles.
• If the client offers radiation oncology technology: we prioritize radiation contouring/treatment planning stakeholders + clinical applications + RT workflow leadership.
• If the client offers clinical research services / CRO capabilities: we prioritize clinical trial operations + study delivery + oncology CRO business development.
• If the client offers education/CME enablement: we prioritize CME/CPD program leadership + scientific education and faculty engagement roles.
• If the client offers patient advocacy / outcomes support: we prioritize patient impact leadership + outcomes/access teams + advocacy summit-aligned roles.

Until the client website is provided, we can only provide a best-fit provisional buyer shortlist (like the table above). Once we have the website, we will upgrade it into an optimized priority-ranked buyer list aligned to the client’s actual buying criteria.

9) Industry selection mapped to the industry list we use

Based on the conference theme (gynecologic cancer prevention/treatment/research, CME/CPD, workshops, radiation contouring, and advocacy), the most appropriate industries from the available industry list typically include:

• Pharmaceuticals
• Biotechnology
• Medical Devices
• Medical Practice
• Hospital & Health Care
• Hospitality (only if the client sells event logistics or travel-related services—otherwise optional)
• Research
• Professional Training & Coaching (if education/training is the offer)
• E-Learning (if oncology education is delivered digitally)
• Events Services (only if the client is an event enablement provider)
• Market Research (if the client provides healthcare insights or evidence analytics)
• Nonprofit Organization Management (if the client sells to advocacy or patient support ecosystems)
• Information Technology & Services (only if the client’s product is healthcare IT, analytics, or clinical workflow software)
• Computer & Network Security (only if the client provides secure healthcare data infrastructure)

Quality rating for attendee/buyer engagement potential (directional)

Because IGCS 2026 includes multidisciplinary clinical topics, workshops, CME/CPD, and an advocacy summit, the buyer engagement potential is typically high for oncology-focused solutions. The exact “best buyer” set depends heavily on what the client product does, which is why we need the client’s website to finalize the target list.

Next step we need from you

Please share the client website URL and a one-sentence description of the product. After that, we will return: optimized buyer company priorities, best job titles, and a final ranked sample table (15–20 buyers) specifically tailored to the client’s needs for IGCS 2026.